Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05461664 |
Recruitment Status :
Not yet recruiting
First Posted : July 18, 2022
Last Update Posted : July 18, 2022
|
Sponsor:
Xinhua Zhang, MD
Collaborators:
Peking University Cancer Hospital & Institute
Fudan University
Peking University People's Hospital
Chinese PLA General Hospital
Xiangya Hospital of Central South University
Peking University Shenzhen Hospital
Nanfang Hospital, Southern Medical University
West China Hospital
Jiangsu Cancer Institute & Hospital
Shanghai Zhongshan Hospital
Sun Yat-sen University
Xijing Hospital
Shengjing Hospital
Shanghai Jiao Tong University School of Medicine
Liaoning Cancer Hospital & Institute
Sixth Affiliated Hospital, Sun Yat-sen University
Fujian Medical University Union Hospital
Cancer Hospital of Guangxi Medical University
Wuhan Union Hospital, China
First Affiliated Hospital of Chongqing Medical University
Chongqing University Cancer Hospital
Information provided by (Responsible Party):
Xinhua Zhang, MD, First Affiliated Hospital, Sun Yat-Sen University
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Not yet recruiting |
---|---|
Estimated Primary Completion Date : | August 31, 2024 |
Estimated Study Completion Date : | August 31, 2024 |
Publications of Results:
Other Publications:
中国临床肿瘤学会胃肠间质瘤专家委员会. 中国胃肠间质瘤诊断治疗共识(2017 年版). 肿瘤综合治疗电子杂志. 2018;4(1): 31-42.
Other Publications: